Dedifferentiation confers MM resistance to both inhibitors of BRAF and MAPK that are associated with loss of melanoma-specific transcription factor (MITF) (Khamari et al., 2018; Tsoi et al., 2018), which is the master regulator of melanocyte differentiation (Müller et al., 2014; Hugo et al., 2015). The gene discussed is MITF; the disease is Miyoshi myopathy.